This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Study of SGR-1505 in Mature B-Cell Neoplasms | MicrobiomeTrials
← Back to trials NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-04-10Est. Completion: 2027-11
Enrollment target: 98 participantsLocations Banner Health - MD Anderson Cancer Center, Gilbert, Arizona, United States Christiana Care Hospital - Helen F Graham Cancer Center, Newark, Delaware, United States Napa Research, Pompano Beach, Florida, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Regional Cancer Care Associates, Hackensack, New Jersey, United States Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States Weill Cornell, New York, New York, United States Montefiore Medical Center, The Bronx, New York, United States Duke University, Durham, North Carolina, United States Gabrail Cancer & Research Center, Canton, Ohio, United States The Ohio State University - The James Cancer Hospital, Columbus, Ohio, United States Oregon Health and Science University - Knight Cancer Institute, Portland, Oregon, United States Rhode Island Hospital, Providence, Rhode Island, United States University of Texas Southwestern, Dallas, Texas, United States Fred Hutchinson Cancer Center, Seattle, Washington, United States Other microbiome trials you might be interested in Non-Hodgkin Lymphoma Burkitt Lymphoma Diffuse Large B-Cell Lymphoma Primary Mediastinal B-cell Lymphoma CD20+ Lymphoblastic Lymphoma Follicular Lymphoma, Grade III
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combin…
Valhalla, United States Est. completion Dec 2026
Endometrial Adenocarcinoma Endometrial Clear Cell Adenocarcinoma
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
AP-HP Hôpital Henri-Mondor, Créteil, France
Institut Gustave Roussy, Villejuif, France
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Ospedale Civile, Alessandria, Italy
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
IRCCS Ospedale San Raffaele, Milan, Italy
AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette, Torino, Italy
Azienda Ospedaliera - Universitaria Integrata di Verona - Ospedale Borgo Roma, Verona, Italy
Institute of Oncology, ARENSIA Exploratory Medicine, Chisinau, Moldova
Uniwersyteckie Centrum Kliniczne, Osrodek Badan Klinicznych Wczesnych Faz, Gdansk, Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, Warsaw, Poland
ARENSIA Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, Bucharest, Romania
ARENSIA Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca, Romania
Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Spain
Hospital Universitario Quironsalud Madrid, Madrid, Spain
START Madrid - CIOCC, Madrid, Spain
START Madrid - Hospital Fundacion Jimenez Diaz, Madrid, Spain
Clinica Universidad de Navarra - Pamplona, Pamplona, Spain
Hospital Clinico Universitario de Salamanca, Salamanca, Spain
ARENSIA Research Clinic at Harmony Health Clinic, Kyiv, Ukraine Endometrial Dedifferentiated Carcinoma
Endometrial Endometrioid Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Mucinous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Endometrioid Adenocarcinoma
Recurrent Endometrial Carcinoma
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink t…
Birmingham, United States Est. completion Jul 30, 2032
Ovarian Cancer
This trial proposes to evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequentia…
Pittsburgh, United States Est. completion Aug 2028